Rankings
▼
Calendar
APLS FY 2021 Earnings — Apellis Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena
APLS
Apellis Pharmaceuticals, Inc.
$3B
FY 2021 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$67M
-73.4% YoY
Gross Profit
$61M
92.2% margin
Operating Income
-$536M
-805.7% margin
Net Income
-$746M
-1121.3% margin
EPS (Diluted)
$-8.84
Cash Flow
Operating Cash Flow
-$563M
Free Cash Flow
-$564M
Stock-Based Comp.
$71M
Balance Sheet
Total Assets
$882M
Total Liabilities
$683M
Stockholders' Equity
$199M
Cash & Equivalents
$640M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$67M
$251M
-73.4%
Gross Profit
$61M
$226M
-72.8%
Operating Income
-$536M
-$214M
-150.9%
Net Income
-$746M
-$345M
-116.4%
← Q4 2020
All Quarters
Q1 2021 →